Glycomet-GP 3 Forte Tablet is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 1000mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to release insulin, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves insulin sensitivity in peripheral tissues, enhancing glucose uptake and utilization. This dual mechanism addresses hyperglycemia through complementary pathways, making Glycomet-GP 3 Forte effective in achieving glycemic control in patients inadequately managed by diet and exercise alone. The tablet is prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is important to monitor blood glucose levels regularly to adjust dosage and minimize the risk of hypoglycemia, a potential side effect primarily associated with Glimepiride. Metformin’s common adverse effects include gastrointestinal disturbances, which often subside with continued use. Glycomet-GP 3 Forte should be used cautiously in patients with renal or hepatic impairment and is contraindicated in conditions predisposing to lactic acidosis. Regular follow-up with healthcare professionals is essential to optimize therapy and ensure patient safety.